Trials / Terminated
TerminatedNCT04142619
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Cellectis S.A. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UCARTCS1A | Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor |
Timeline
- Start date
- 2019-11-21
- Primary completion
- 2023-06-18
- Completion
- 2023-06-18
- First posted
- 2019-10-29
- Last updated
- 2023-09-22
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04142619. Inclusion in this directory is not an endorsement.